Susceptibility-weighted imaging: technical essentials and clinical neurologic applications

S Haller, EM Haacke, MM Thurnher, F Barkhof - Radiology, 2021 - pubs.rsna.org
Susceptibility-weighted imaging (SWI) evolved from simple two-dimensional T2*-weighted
sequences to three-dimensional sequences with improved spatial resolution and enhanced …

Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease

JY Lee, A Martin-Bastida, A Murueta-Goyena… - Nature Reviews …, 2022 - nature.com
Parkinson disease (PD) is a progressive disorder characterized by dopaminergic
neurodegeneration in the brain. The development of parkinsonism is preceded by a long …

Neuroimaging in dementia: more than typical Alzheimer disease

S Haller, HR Jäger, MW Vernooij, F Barkhof - Radiology, 2023 - pubs.rsna.org
Alzheimer disease (AD) is the most common cause of dementia. The prevailing theory of the
underlying pathology assumes amyloid accumulation followed by tau protein aggregation …

Imaging the substantia nigra in Parkinson disease and other Parkinsonian syndromes

YJ Bae, JM Kim, CH Sohn, JH Choi, BS Choi, YS Song… - Radiology, 2021 - pubs.rsna.org
Parkinson disease is characterized by dopaminergic cell loss in the substantia nigra of the
midbrain. There are various imaging markers for Parkinson disease. Recent advances in …

Magnetic resonance imaging for the diagnosis of Parkinson's disease

B Heim, F Krismer, R De Marzi, K Seppi - Journal of neural transmission, 2017 - Springer
The differential diagnosis of parkinsonian syndromes is considered one of the most
challenging in neurology and error rates in the clinical diagnosis can be high even at …

Prodromal Parkinson's disease: the decade past, the decade to come

RB Postuma, D Berg - Movement disorders, 2019 - Wiley Online Library
The past decade has seen a dramatic expansion of the field of prodromal PD. Ten years
ago, there were only six known prodromal markers of disease, none of which had more than …

Neuroimaging advances in Parkinson's disease and atypical Parkinsonian syndromes

U Saeed, AE Lang, M Masellis - Frontiers in neurology, 2020 - frontiersin.org
Parkinson's disease (PD) and atypical Parkinsonian syndromes are progressive
heterogeneous neurodegenerative diseases that share clinical characteristic of …

Alpha-synuclein as a biomarker of Parkinson's disease: good, but not good enough

U Ganguly, S Singh, S Pal, S Prasad… - Frontiers in aging …, 2021 - frontiersin.org
Parkinson's disease (PD) is the second most common neurodegenerative disorder of the
elderly, presenting primarily with symptoms of motor impairment. The disease is diagnosed …

Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts

U Saeed, J Compagnone, RI Aviv, AP Strafella… - Translational …, 2017 - Springer
Two centuries ago in 1817, James Parkinson provided the first medical description of
Parkinson's disease, later refined by Jean-Martin Charcot in the mid-to-late 19th century to …

The concept of prodromal Parkinson's disease

P Mahlknecht, K Seppi… - Journal of Parkinson's …, 2015 - content.iospress.com
Parkinson's disease (PD) is currently clinically defined by a set of cardinal motor features
centred on the presence of bradykinesia and at least one additional motor symptom out of …